Adocia
Products and platforms
- Pipeline
- Technology Platforms
Careers
Partnering
Investors
Media
Contact
- Contact us
- Map and accessibility

Investors
Media
- Press releases
- Media

EN
- FR

Adocia announces Positive Topline Results of Phase 1b Study for M1Pram in People with type 1 Diabetes.

Previous articleADO09, a co-formulation of amylin analog pramlintide and human insulin analog A21G, reduces postprandial blood sugar compared to insulin lispro in type 1 diabetes, Dr. Grégory Meiffren, September 10, 2020, Société Francophone du Diabète, Virtual Event.

Next articleAdocia announces a Video Conference to Present a Corporate Update Wednesday, September 23rd, 2020

Adocia
Products and platforms
Careers
Partnering
Investors
Media
Contact

Contact us

+33(0)4 72 610 610 contact@adocia.com

Adocia
115 Avenue Lacassagne
69003 Lyon, France

2026 © Adocia

Site plan
Legal notice
Privacy policy and cookies policy
Managing cookies

Website by

Un Brin de Campagne